ADAR1 Capital Management, LLC
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 18, 2026), ADAR1 Capital Management, LLC reported 248 stock positions worth $1.3 billion. Its top holding was Abivax SA-ADR (ABVX) at 13.3% of the portfolio, followed by Protagonist Therapeutics (PTGX, 6.9%) and Roivant Sciences (ROIV, 5.6%). Compared with Q3 2025, it opened 78 new positions, sold out of 26, added to 79 and reduced 46. The biggest buy was Avidity Biosciences (RNAM, shares +919%) and the biggest sale Keros Therapeutics (KROS, shares −100%).
- Most Recent 13F
- Q2 2026
- Location
- AUSTIN, TX
- CIK
- 0001940272
- Portfolio Value
- $1.3B (Q4 2025)
- SEC Filing
- 0001940272-26-000003 ↗ filed Feb 18, 2026
Holdings Value
Holdings 248 stocks · $1.3B
| ABVX Abivax SA-ADR | 13.29% | 1,317,329 | $177.6M | Reduce -2.5% |
| PTGX Protagonist Therapeutics Inc. | 6.85% | 1,049,168 | $91.6M | Add +6.1% |
| ROIV Roivant Sciences Ltd. | 5.57% | 3,428,962 | $74.4M | Add +2.4% |
| IMVT Immunovant Inc. | 4.72% | 2,480,968 | $63.1M | Add +10.7% |
| RNAM Avidity Biosciences Inc. | 2.95% | 546,534 | $39.4M | Add +918.6% |
| BOXX Alpha Architect 1-3 MNTH Box | 2.90% | 337,125 | $38.8M | No change |
| SPY SS SPDR S&P 500 ETF Trust-US | 2.79% | 54,684 | $37.3M | No change |
| CYTK Cytokinetics Inc. | 2.57% | 540,166 | $34.3M | Add +4.1% |
| SEPN Septerna Inc. | 2.41% | 1,157,611 | $32.3M | Reduce -1.6% |
| ABUS Arbutus Biopharma Corp. | 1.95% | 5,415,109 | $26.0M | Add +86.5% |
| ZLAB Zai Lab Ltd.-ADR | 1.64% | 1,246,520 | $22.0M | Add +43.5% |
| TERN Terns Pharmaceuticals Inc. | 1.64% | 541,615 | $21.9M | Add +5316.1% |
| CTMX Cytomx Therapeutics Inc. | 1.33% | 4,182,769 | $17.8M | Add +3.4% |
| CLDX Celldex Therapeutics Inc. | 1.31% | 646,767 | $17.6M | Add +491.0% |
| RAPT Rapt Therapeutics Inc. | 1.29% | 509,679 | $17.3M | Add +0.4% |
| IKT Inhibikase Therapeutics Inc. | 1.24% | 8,063,949 | $16.5M | Add +53.7% |
| BBIO Bridgebio Pharma Inc. | 1.22% | 213,414 | $16.3M | Reduce -21.9% |
| MNPR Monopar Therapeutics Inc. | 1.14% | 233,908 | $15.3M | Add +79.9% |
| PCVX Vaxcyte Inc. | 1.09% | 315,642 | $14.6M | Add +48.1% |
| CRNX Crinetics Pharmaceuticals Inc. | 1.08% | 309,368 | $14.4M | Add +24.6% |
| FULC Fulcrum Therapeutics Inc. | 1.06% | 1,253,749 | $14.2M | Add +267.0% |
| PRTA Prothena Corp. PLC | 1.04% | 1,457,764 | $13.9M | Reduce -0.8% |
| LXEO Lexeo Therapeutics Inc. | 1.03% | 1,393,161 | $13.8M | Reduce -9.1% |
| TSHA Taysha Gene Therapies Inc. | 1.03% | 2,495,809 | $13.7M | Reduce -12.0% |
| CDTX Cidara Therapeutics Inc. | 0.99% | 59,677 | $13.2M | Add +177.3% |
| IVA Inventiva SA - ADR | 0.94% | 2,709,846 | $12.6M | New |
| ESTA Establishment Labs Holdings | 0.93% | 171,422 | $12.5M | Add +89.0% |
| BIL SS SPDR BB 1-3M T-Bill ETF | 0.93% | 135,585 | $12.4M | No change |
| REPL Replimune Group Inc. | 0.90% | 1,241,322 | $12.1M | Add +26.8% |
| IONS Ionis Pharmaceuticals Inc. | 0.87% | 147,130 | $11.6M | Add +9.9% |
| RVMD Revolution Medicines Inc. | 0.86% | 145,079 | $11.6M | Add +4.3% |
| AMLX Amylyx Pharmaceuticals Inc. | 0.80% | 890,356 | $10.8M | Add +2.8% |
| CGON CG Oncology Inc. | 0.80% | 258,139 | $10.7M | Add +3.7% |
| TFX Teleflex Inc. | 0.74% | 80,627 | $9.8M | New |
| IVVD Invivyd Inc. | 0.72% | 3,899,397 | $9.6M | Reduce -47.1% |
| REGN Regeneron Pharmaceuticals | 0.70% | 12,051 | $9.3M | Reduce -23.2% |
| XENE Xenon Pharmaceuticals Inc. | 0.68% | 203,969 | $9.1M | Add +7.9% |
| EQ Equillium Inc. | 0.65% | 5,608,078 | $8.7M | Add +0.9% |
| SVRA Savara Inc. | 0.63% | 1,405,452 | $8.5M | Reduce -29.3% |
| MAZE Maze Therapeutics Inc. | 0.56% | 179,532 | $7.4M | Add +589.3% |
| TEVA Teva Pharmaceutical-SP ADR | 0.55% | 235,971 | $7.4M | Reduce -11.9% |
| CBIO Crescent Biopharma Inc. | 0.54% | 606,000 | $7.2M | New |
| OVID Ovid Therapeutics Inc. | 0.52% | 4,285,000 | $7.0M | Add +33256.7% |
| BLTE Belite Bio Inc. - ADR | 0.48% | 39,839 | $6.4M | New |
| VRTX Vertex Pharmaceuticals Inc. | 0.47% | 13,716 | $6.2M | Add +95.9% |
| BHF Brighthouse Financial Inc. | 0.46% | 95,523 | $6.2M | Add +855.2% |
| AVR Anteris Technologies Global | 0.46% | 1,238,777 | $6.2M | Add +526.9% |
| AAM Aa Mission Acquisition Cor-A | 0.46% | 578,359 | $6.2M | No change |
| TARA Protara Therapeutic Inc. | 0.45% | 1,136,799 | $6.1M | Add +3127.4% |
| FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR | 0.45% | 456,720 | $6.0M | Reduce -39.1% |
| DHR Danaher Corp. | 0.44% | 25,600 | $5.9M | New |
| CLYM Climb Bio Inc. | 0.43% | 1,432,475 | $5.7M | Add +972.8% |
| QURE Uniqure NV | 0.42% | 235,155 | $5.6M | Add +76.4% |
| RYTM Rhythm Pharmaceuticals Inc. | 0.41% | 51,349 | $5.5M | Add +3.6% |
| OACCU Oaktree Acquisition III Life | 0.41% | 516,482 | $5.5M | No change |
| ASND Ascendis Pharma A/S | 0.40% | 25,314 | $5.4M | Reduce -30.4% |
| AGIO Agios Pharmaceuticals Inc. | 0.38% | 188,000 | $5.1M | Add +408.1% |
| SPRB Spruce Biosciences Inc. | 0.38% | 58,000 | $5.1M | New |
| MLYS Mineralys Therapeutics Inc. | 0.37% | 136,231 | $4.9M | Add +74.1% |
| KRYS Krystal Biotech Inc. | 0.37% | 20,014 | $4.9M | Add +8.1% |
| PALI Palisade Bio Inc. | 0.35% | 2,004,845 | $4.7M | New |
| SPRY Ars Pharmaceuticals Inc. | 0.32% | 369,569 | $4.3M | Add +524.0% |
| BIIB Biogen Inc. | 0.32% | 24,300 | $4.3M | Add +35.0% |
| NAMS Newamsterdam Pharma Co. NV | 0.31% | 118,623 | $4.2M | Add +3.7% |
| AEXA American Exceptionalism Class A | 0.30% | 357,539 | $4.1M | Add +615.1% |
| ARWR Arrowhead Pharmaceuticals Inc. | 0.29% | 58,200 | $3.9M | Add +16.9% |
| ATAIBECKLEY INC | 0.28% | 913,242 | $3.7M | No change |
| CRVS Corvus Pharmaceuticals Inc. | 0.27% | 465,875 | $3.6M | New |
| JANX Janux Therapeutics Inc. | 0.25% | 245,452 | $3.4M | Reduce -30.1% |
| GLUE Monte Rosa Therapeutics Inc. | 0.25% | 215,752 | $3.4M | No change |
| AVDL Avadel Pharmaceuticals Ltd. | 0.24% | 150,532 | $3.2M | New |
| CTNM Contineum Therapeutics Inc. Class A | 0.24% | 278,961 | $3.2M | Add +257.8% |
| EVMN Evommune Inc. | 0.24% | 184,062 | $3.2M | New |
| SNY Sanofi-ADR | 0.23% | 63,474 | $3.1M | Reduce -14.5% |
| SRRK Scholar Rock Holding Corp. | 0.23% | 69,589 | $3.1M | Add +246.4% |
| NKTR Nektar Therapeutics | 0.23% | 72,031 | $3.0M | Add +0.0% |
| IWM iShares Russell 2000 ETF | 0.22% | 12,070 | $3.0M | New |
| ZURA Zura Bio Ltd. | 0.22% | 562,065 | $2.9M | Reduce -13.8% |
| OKUR Onkure Therapeutics Inc. Class A | 0.22% | 1,014,158 | $2.9M | New |
| URGN Urogen Pharma Ltd. | 0.22% | 125,375 | $2.9M | Add +258.2% |
| LONA Leonabio Inc. filed as ATHIRA PHARMA INC | 0.22% | 393,701 | $2.9M | New |
| BBOT Bridgebio Oncology Therapeut | 0.21% | 226,248 | $2.8M | Reduce -54.9% |
| ELDN Eledon Pharmaceuticals Inc. | 0.21% | 1,821,812 | $2.8M | New |
| ENGN Engene Holdings Inc. | 0.21% | 303,686 | $2.7M | New |
| DVAX Dynavax Technologies Corp. | 0.20% | 170,000 | $2.6M | No change |
| INO Inovio Pharmaceuticals Inc. | 0.19% | 1,485,008 | $2.6M | New |
| VRDN Viridian Therapeutics Inc. | 0.18% | 77,198 | $2.4M | Reduce -24.1% |
| PHVS Pharvaris NV | 0.18% | 85,528 | $2.4M | Add +150.6% |
| CRBP Corbus Pharmaceuticals Holdi | 0.17% | 286,781 | $2.3M | Add +2711.6% |
| ATXS Astria Therapeutics Inc. | 0.17% | 173,557 | $2.3M | Reduce -10.5% |
| DCTH Delcath Systems Inc. | 0.17% | 224,385 | $2.3M | No change |
| EWTX Edgewise Therapeutics Inc. | 0.17% | 90,999 | $2.3M | Add +127.5% |
| GRCE Grace Therapeutics Inc. | 0.17% | 641,988 | $2.2M | Add +83.2% |
| RGNX Regenxbio Inc. | 0.16% | 144,848 | $2.1M | Reduce -29.5% |
| ACLX Arcellx Inc. | 0.15% | 31,484 | $2.1M | No change |
| OLMA Olema Pharmaceuticals Inc. | 0.15% | 81,399 | $2.0M | Add +124.9% |
| MASI Masimo Corp. | 0.15% | 15,000 | $2.0M | No change |
| HELP Cybin Inc. | 0.15% | 238,390 | $2.0M | Add +616.4% |
| SLNO Soleno Therapeutics Inc. | 0.14% | 41,830 | $1.9M | Add +65.8% |
| ABOS Acumen Pharmaceuticals Inc. | 0.14% | 891,183 | $1.9M | No change |
Options reported separately and not counted above: IWM puts ($6.8M), AAM calls ($4.3M), GUTS calls ($3.1M), AQST puts ($1.6M), GOSS puts ($1.4M), OMER puts ($1.3M), URGN calls ($937K), KVACF calls ($881K), LQDA puts ($845K), FULC calls ($735K), QURE calls ($718K), CTMX calls ($426K), and 9 more.
Other holdings (1): bonds, preferreds, convertibles and warrants · $41K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| ASPCR A Spac III Acquisition Corp. | RIGHT 01/02/2026 | 215,000 | $41K | No change |
Total filed on the 13F, all lines: $1.3B.
Portfolio Sells Q3 2025 → Q4 2025
| KROS Keros Therapeutics Inc. | Reduce -99.7% | 0.03% | −8.48 |
| ETNB 89BIO Inc. | Sold out | 0.00% | −3.10 |
| BIOA Bioage Labs Inc. | Reduce -92.8% | 0.13% | −0.97 |
| MTSR Metsera Inc. | Sold out | 0.00% | −0.80 |
| RZLT Rezolute Inc. | Reduce -95.3% | 0.01% | −0.76 |
| SRPT Sarepta Therapeutics Inc. | Reduce -91.8% | 0.05% | −0.63 |
| JANX Janux Therapeutics Inc. | Reduce -30.1% | 0.25% | −0.60 |
| VRNA Verona Pharma Ltd. | Sold out | 0.00% | −0.55 |
| UTHR United Therapeutics Corp. | Reduce -83.0% | 0.07% | −0.40 |
| VKTX Viking Therapeutics Inc. | Reduce -84.9% | 0.07% | −0.39 |
| PRTA Prothena Corp. PLC | Reduce -0.8% | 1.04% | −0.39 |
| BBOT Bridgebio Oncology Therapeut | Reduce -54.9% | 0.21% | −0.37 |
| FRNM Freenome Inc. | Reduce -39.1% | 0.45% | −0.34 |
| ASND Ascendis Pharma A/S | Reduce -30.4% | 0.40% | −0.32 |
| MRUS Merus NV | Sold out | 0.00% | −0.31 |
| ASPC A Spac III Acquisition Class A | Sold out | 0.00% | −0.22 |
| KNSA Kiniksa Pharmaceuticals Inte | Reduce -61.8% | 0.09% | −0.20 |
| BBIO Bridgebio Pharma Inc. | Reduce -21.9% | 1.22% | −0.20 |
| KRRO Korro Bio Inc. | Sold out | 0.00% | −0.19 |
| MDGL Madrigal Pharmaceuticals Inc. | Reduce -81.7% | 0.04% | −0.18 |
| REGN Regeneron Pharmaceuticals | Reduce -23.2% | 0.70% | −0.18 |
| SNY Sanofi-ADR | Reduce -14.5% | 0.23% | −0.12 |
| QUINCE THERAPEUTICS INC | Reduce -94.5% | 0.01% | −0.12 |
| MLTX Moonlake Immunotherapeutics | Sold out | 0.00% | −0.11 |
| SMMT Summit Therapeutics Inc. | Reduce -10.8% | 0.12% | −0.09 |
| IVVD Invivyd Inc. | Reduce -47.1% | 0.72% | −0.09 |
| WVE Wave Life Sciences Ltd. | Sold out | 0.00% | −0.09 |
| XNCR Xencor Inc. | Reduce -56.4% | 0.06% | −0.09 |
| MRK Merck & Co. Inc. | Reduce -48.0% | 0.08% | −0.08 |
| OABI Omniab Inc. | Reduce -35.6% | 0.10% | −0.08 |
| LLY Eli Lilly & Co. | Sold out | 0.00% | −0.08 |
| SVRA Savara Inc. | Reduce -29.3% | 0.63% | −0.07 |
| LITS Lite Strategy Inc. | Reduce -77.0% | 0.01% | −0.06 |
| RCKT Rocket Pharmaceuticals Inc. | Reduce -17.4% | 0.12% | −0.06 |
| ZURA Zura Bio Ltd. | Reduce -13.8% | 0.22% | −0.06 |
| CNTA Centessa Pharmaceuticals Ltd. | Reduce -28.1% | 0.07% | −0.06 |
| LENZ Lenz Therapeutics Inc. | Sold out | 0.00% | −0.05 |
| NUVL Nuvalent Inc. Class A | Reduce -42.2% | 0.05% | −0.05 |
| INTELLIGENT BIO SOLUTIONS IN | Sold out | 0.00% | −0.04 |
| DAY Dayforce Inc. | Reduce -50.0% | 0.03% | −0.04 |
| GPCR Structure Therapeutics Inc. | Sold out | 0.00% | −0.04 |
| RGNX Regenxbio Inc. | Reduce -29.5% | 0.16% | −0.04 |
| AVTX Avalo Therapeutics Inc. | Sold out | 0.00% | −0.04 |
| TECX Tectonic Therapeutic Inc. | Reduce -46.4% | 0.05% | −0.04 |
| VRDN Viridian Therapeutics Inc. | Reduce -24.1% | 0.18% | −0.04 |
| ANSC Agriculture & Natural Soluti | Sold out | 0.00% | −0.03 |
| AKRO Akero Therapeutics Inc. | Sold out | 0.00% | −0.03 |
| GERN Geron Corp. | Reduce -26.3% | 0.03% | −0.03 |
| HRMY Harmony Biosciences Holdings | Sold out | 0.00% | −0.03 |
| RARE Ultragenyx Pharmaceutical Inc. | Sold out | 0.00% | −0.03 |
Portfolio Buys Q3 2025 → Q4 2025
| RNAM Avidity Biosciences Inc. | Add +918.6% | 2.95% | +2.72 |
| TERN Terns Pharmaceuticals Inc. | Add +5316.1% | 1.64% | +1.63 |
| IMVT Immunovant Inc. | Add +10.7% | 4.72% | +1.11 |
| CLDX Celldex Therapeutics Inc. | Add +491.0% | 1.31% | +1.03 |
| IVA Inventiva SA - ADR | New | 0.94% | +0.94 |
| CDTX Cidara Therapeutics Inc. | Add +177.3% | 0.99% | +0.78 |
| FULC Fulcrum Therapeutics Inc. | Add +267.0% | 1.06% | +0.75 |
| TFX Teleflex Inc. | New | 0.74% | +0.74 |
| ABUS Arbutus Biopharma Corp. | Add +86.5% | 1.95% | +0.63 |
| ESTA Establishment Labs Holdings | Add +89.0% | 0.93% | +0.56 |
| CBIO Crescent Biopharma Inc. | New | 0.54% | +0.54 |
| OVID Ovid Therapeutics Inc. | Add +33256.7% | 0.52% | +0.52 |
| ROIV Roivant Sciences Ltd. | Add +2.4% | 5.57% | +0.51 |
| REPL Replimune Group Inc. | Add +26.8% | 0.90% | +0.49 |
| MAZE Maze Therapeutics Inc. | Add +589.3% | 0.56% | +0.49 |
| BLTE Belite Bio Inc. - ADR | New | 0.48% | +0.48 |
| DHR Danaher Corp. | New | 0.44% | +0.44 |
| TARA Protara Therapeutic Inc. | Add +3127.4% | 0.45% | +0.44 |
| BHF Brighthouse Financial Inc. | Add +855.2% | 0.46% | +0.41 |
| CLYM Climb Bio Inc. | Add +972.8% | 0.43% | +0.40 |
| IKT Inhibikase Therapeutics Inc. | Add +53.7% | 1.24% | +0.39 |
| SPRB Spruce Biosciences Inc. | New | 0.38% | +0.38 |
| AVR Anteris Technologies Global | Add +526.9% | 0.46% | +0.37 |
| PALI Palisade Bio Inc. | New | 0.35% | +0.35 |
| PCVX Vaxcyte Inc. | Add +48.1% | 1.09% | +0.32 |
| PTGX Protagonist Therapeutics Inc. | Add +6.1% | 6.85% | +0.30 |
| CRVS Corvus Pharmaceuticals Inc. | New | 0.27% | +0.27 |
| SPRY Ars Pharmaceuticals Inc. | Add +524.0% | 0.32% | +0.26 |
| AEXA American Exceptionalism Class A | Add +615.1% | 0.30% | +0.25 |
| AVDL Avadel Pharmaceuticals Ltd. | New | 0.24% | +0.24 |
| EVMN Evommune Inc. | New | 0.24% | +0.24 |
| AGIO Agios Pharmaceuticals Inc. | Add +408.1% | 0.38% | +0.23 |
| IWM iShares Russell 2000 ETF | New | 0.22% | +0.22 |
| OKUR Onkure Therapeutics Inc. Class A | New | 0.22% | +0.22 |
| LONA Leonabio Inc. | New | 0.22% | +0.22 |
| RVMD Revolution Medicines Inc. | Add +4.3% | 0.86% | +0.22 |
| ELDN Eledon Pharmaceuticals Inc. | New | 0.21% | +0.21 |
| ENGN Engene Holdings Inc. | New | 0.21% | +0.21 |
| INO Inovio Pharmaceuticals Inc. | New | 0.19% | +0.19 |
| VRTX Vertex Pharmaceuticals Inc. | Add +95.9% | 0.47% | +0.19 |
| CRBP Corbus Pharmaceuticals Holdi | Add +2711.6% | 0.17% | +0.16 |
| SRRK Scholar Rock Holding Corp. | Add +246.4% | 0.23% | +0.15 |
| URGN Urogen Pharma Ltd. | Add +258.2% | 0.22% | +0.15 |
| CTNM Contineum Therapeutics Inc. Class A | Add +257.8% | 0.24% | +0.15 |
| GMED Globus Medical Inc. Class A | New | 0.13% | +0.13 |
| ALEC Alector Inc. | New | 0.13% | +0.13 |
| HELP Cybin Inc. | Add +616.4% | 0.15% | +0.13 |
| ARWR Arrowhead Pharmaceuticals Inc. | Add +16.9% | 0.29% | +0.12 |
| OLMA Olema Pharmaceuticals Inc. | Add +124.9% | 0.15% | +0.12 |
| EWTX Edgewise Therapeutics Inc. | Add +127.5% | 0.17% | +0.10 |
Options Activity Q3 2025 → Q4 2025
| SPY SS SPDR S&P 500 ETF Trust-US | put | Sold out | 45,500 | $30.3Mbefore exit |
| IWM iShares Russell 2000 ETF | put | New | 27,500 | $6.8M |
| XBI SS SPDR S&P Biotech ETF | put | Sold out | 40,000 | $4.0Mbefore exit |
| GUTS Fractyl Health Inc. | call | New | 1,428,571 | $3.1M |
| AQST Aquestive Therapeutics Inc. | put | New | 254,000 | $1.6M |
| GOSS Gossamer Bio Inc. | put | New | 463,200 | $1.4M |
| OMER Omeros Corp. | put | New | 75,000 | $1.3M |
| LQDA Liquidia Corp. | put | New | 24,500 | $845K |
| FULC Fulcrum Therapeutics Inc. | call | Reduce -13.3% | 65,000 | $735K |
| QURE Uniqure NV | call | Reduce -85.0% | 30,000 | $718K |
| CTMX Cytomx Therapeutics Inc. | call | New | 100,000 | $426K |
| NVCR Novocure Ltd. | call | Sold out | 30,000 | $388Kbefore exit |
| BHVN Biohaven Ltd. | call | Sold out | 25,000 | $375Kbefore exit |
| QUINCE THERAPEUTICS INC | put | New | 80,000 | $268K |
| OLMA Olema Pharmaceuticals Inc. | call | Sold out | 25,000 | $245Kbefore exit |
| REPL Replimune Group Inc. | call | Reduce -50.0% | 25,000 | $243K |
| RARE Ultragenyx Pharmaceutical Inc. | call | New | 10,000 | $230K |
| DYN Dyne Therapeutics Inc. | call | Reduce -50.0% | 10,000 | $196K |
| ATYR Atyr Pharma Inc. | put | Sold out | 222,500 | $161Kbefore exit |
| OTLK Outlook Therapeutics Inc. | put | New | 100,000 | $158K |
| INO Inovio Pharmaceuticals Inc. | call | New | 75,500 | $131K |
| MLTX Moonlake Immunotherapeutics | call | Sold out | 17,000 | $122Kbefore exit |
| GOSS Gossamer Bio Inc. | call | Reduce -36.3% | 35,100 | $109K |
| IOVA Iovance Biotherapeutics Inc. | call | Sold out | 50,000 | $109Kbefore exit |
| VTGN Vistagen Therapeutics Inc. | put | New | 120,000 | $79K |
| ATYR Atyr Pharma Inc. | call | Sold out | 84,800 | $61Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q3 2025 → Q4 2025
| BRIDGEBIO PHARMA INC (BBIO 2.5 03/15/27) | NOTE 2.500% 3/1 · principal | Sold out | 20,000 | $2.8Mbefore exit |
| BRIDGEBIO PHARMA INC (BBIO 2.25 02/01/29) | NOTE 2.250% 2/0 · principal | Sold out | 45,000 | $44Kbefore exit |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 260 | $2.1B | ABVX, PTGX, ROIV, SPY, IMVT |
| Q1 2026 | 290 | $1.6B | ABVX, PTGX, ROIV, IMVT, SPY |
| Q4 2025Amended | 248 | $1.3B | ABVX, PTGX, ROIV, IMVT, RNAM |
| Q3 2025 | 196 | $1.0B | ABVX, KROS, PTGX, ROIV, BOXX |
| Q2 2025 | 192 | $609.1M | KROS, PTGX, BOXX, ZLAB, ABVX |
| Q1 2025 | 185 | $505.1M | PTGX, BOXX, ROIV, ZLAB, IMVT |
| Q4 2024 | 185 | $469.3M | ROIV, PTGX, BOXX, ZLAB, IMVT |
| Q3 2024 | 244 | $596.5M | CYTK, PTGX, BBIO, BOXX, ROIV |
| Q2 2024 | 231 | $496.6M | PTGX, CYTK, ROIV, BOXX, BBIO |
| Q1 2024 | 223 | $366.2M | BOXX, ROIV, ALNY, PTGX, CYTK |